Default company panoramic image
Logo

Thetis Pharmaceuticals LLC

Leveraging existing active pharmaceutical ingredients to chemically create new molecular entities with enhanced PK and efficacy

  • Stage Product In Development
  • Industry Biotechnology
  • Location Fairfield, CT, USA
  • Currency USD
  • Founded January 2011
  • Employees 3
  • Website thetispharma.com

Company Summary

Founded in January 2011, Thetis is an emerging pharmaceutical company developing a portfolio of prescription drugs for the treatment of type 2 diabetes, hypertriglyceridemia and dyslipidemia. All have blockbuster potential as first-in-class or best-in-class opportunities in major pharmaceutical markets. EPA, a principal active ingredient in omega-3 fatty acids, is uniquely incorporated into the chemical structures of the Thetis compounds.

Team

  • Default avatar
    Frank Sciavolino, PhD
    Chief Scientific Officer

    Dr. Sciavolino has more than 40 years experience in the pharmaceutical industry. At Pfizer, he was the enabling force behind Zithromax and the Cox-2 Alliance with Pharmacia. Dr. Sciavolino has holds over 30 patents. He has a PhD in organic chemistry from the University of Michigan and BS in Pharmacy from St. John's University.

  • Default avatar
    Banavara L. Mylaria, PhD
    Chief Technology Officer

    Dr. Mylari has over 40 years experience in the pharmaceutical industry. At Pfizer he worked on a number of successful projects in diabetes, antibacterials, antiprotozoals, and anti-inflammatory drugs. He played a key role in the commercialization of salinomycin, and a lead role in the development of zopolrestat for diabetic complications. Dr. Mylari obtained his PhD in organic chemistry from Indiana University, and holds over 50 US patents.

  • Default avatar
    G. Alexander (Zan) Fleming, MD
    Senior Medical Advisor

    Dr. Fleming has extensive FDA regulatory experience. He had responsibility at the FDA for the review of new drug applications (NDAs) in the areas of metabolic and endocrine disorders, and lipid-lowering agents. He is Board Certified in Internal Medicine, and Endocrinology and Metabolism. Dr. Fleming is a member of numerous scientific advisory boards and expert committees and is a Founder, President/CEO of the consulting firm, Kinexum.

  • Default avatar
    Gary Mathias
    Chief Financial Officer

    Mr. Mathias has been involved in the healthcare arena as an entrepreneur, investor and banker for 25 years. He is managing director of Carter Morse & Mathias (an investment banking firm) and previously was SVP in the Healthcare Group of GE Equity and chief operating officer of Diabetes Support Systems. Mr. Mathias has a BA in Economics from Harvard College and MBA from the Yale School of Management.

Advisors

  • Default avatar
    Lathrop & Gage (IP)
    Lawyer
    Unconfirmed
    Default avatar
    JH Cohn LLP
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Connecticut Innovations
    Unconfirmed
    Default avatar
    Stonehenge Growth Capital
    Unconfirmed
    Default avatar
    River Valley Investors
    Unconfirmed